Baird Starts Trius Therapeutics (TSRX) at Outperform; High Quality, De-Risked Story

Baird initiates coverage on Trius Therapeutics (NASDAQ: TSRX) with an Outperform. PT $13.00.

Baird analyst says, "We view TSRX as a very high quality company and recently de-risked story. Lead product tedizolid has a good chance to achieve a differentiated profile and carve-out a nice place in the MRSA hospital infections market. The Phase 3 update 12/19 was a positive and critical de-risking event, and the stock still offers an excellent entry point and potential for significant value creation over a multi-year period."

For an analyst ratings summary and ratings history on Trius Therapeutics click here. For more ratings news on Trius Therapeutics click here.

Shares of Trius Therapeutics closed at $6.75 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Savers Value Village closes 23M share secondary offering
• Evercore ISI Starts Alvotech SA (ALVO) at Outperform
• BMO Capital Starts Energy Fuels (UUUU) at Outperform